sulfamethoxazole (TMP/SMX) the following day for pneumonia caused by TMP/SMX-susceptible *S. maltophilia*. 

**Background.** Ceftazidime-avibactam (CAZ-AVI) is a β-lactam/β-lactamase inhibitor combination that can inhibit class A, C, and some class D β-lactamases. Resistance caused by these β-lactamases often results in multidrug resistance (MDR). This study evaluated the in vitro activity of CAZ-AVI and comparators against MDR Enterobacteriales and *Pseudomonas aeruginosa* isolates collected from patients in Latin America.

**Methods.** Non-duplicate clinical isolates were collected in 2018-2019 in 10 countries in Latin America. Susceptibility testing was performed using CLSI broth microdilution and interpreted using CLSI 2021 and FDA (tigecycline) breakpoints. MDR was defined as resistant (R) to ≥5 of 7 sentinel drugs: amikacin (AKM), aztreonam (ATM), cefepime (FEP), colistin (CST), levofloxacin (LVX), meropenem (MEM), and piperacillin-tazobactam (TZP).

**Results.** The activity of CAZ-AVI and comparators against all isolates and MDR subsets is shown in the table. MDR rates for the studied species ranged from 16.3% for *E. cloacae* and *K. pneumoniae* CAZ-AVI: active against 98% of all isolates and 47% of MDR isolates; no other studied drug was more active. The three most common MDR phenotypes among *P. aeruginosa* were: 1) R to all sentinel drugs except CST (n=85, 19.7% of all MDR isolates; 24.7% S to CAZ-AVI), and 3) R to all sentinel drugs except AMK and CST (n=42, 9.7% of all MDR isolates; 24.3% S to CAZ-AVI), 2) R to all sentinel drugs except AMK and CST (n=42, 9.7% of all MDR isolates; 24.3% S to CAZ-AVI), and 3) R to all sentinel drugs except AMK and CST (n=42, 9.7% of all MDR isolates; 24.7% S to CAZ-AVI), and 3) R to all sentinel drugs except AMK and CST (n=42, 9.7% of all MDR isolates; 24.7% S to CAZ-AVI).

**Conclusion.** Ceftazidime-avibactam can be an effective treatment option for infections caused by MDR Enterobacteriales and *P. aeruginosa* collected in Latin America.

**Disclosures.** Sibyille Lob, PhD; IHMA (Employee); Pfizer, Inc. (Independent Contractor) Gregory Stone, PhD; AstraZeneca (Shareholder, Former Employee); Pfizer, Inc. (Employee); Daniel F. Sahm, PhD; IHMA (Employee); Pfizer, Inc. (Independent Contractor)